Kiniksa (KNSA) Stock Surges As Q3 Earnings Strengthen Its Growth Story

Kiniksa Pharmaceuticals International lit up the tape after its Q3 2026 release, with the stock jumping 22.2% to US$89.20 by the close. That is a big emotional swing for a single session. The hook is clear. Reported revenue of US$285.97m and net income of US$47.35m landed solidly, and basic earnings per share of US$0.61 put a clean profit figure in front of a market that had already been debating a 63.5x P/E. Today appeared less like a sudden story change and more like investors responding to a strong positive trend.

Impressed by Kiniksa Pharmaceuticals International posting US$285.97m in revenue and positive earnings, but wondering if a 63.5x P/E feels too rich for your taste? Take a look at our screener of high quality companies with stronger balance sheets and fundamentals in the list of solid balance sheet and fundamentals stocks (24 results).

Q3 2026 Earnings Summary

• Total Revenue (Q3 2026 vs. Q3 2025): US$285.97m vs. US$180.86m (up about 58%)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$47.35m vs. US$18.44m (up about 157%)
• Basic EPS (Q3 2026 vs. Q3 2025): US$0.61 vs. US$0.25 (up about 146%)
• Products in Phase II (end of Q3 2026 vs. Q3 2025): 3 vs. 2 (pipeline expanded)

ARCALYST sales jumped and Kiniksa raised full-year guidance again. Ask Charlie what Kiniksa’s IL-1 franchise means for ARCALYST’s runway.

Kiniksa bull case hinges on IL‑1 execution milestones

The upbeat view on Kiniksa Pharmaceuticals International rests on ARCALYST reach and the build out of a broader IL‑1 franchise. That story is now testable against concrete execution.

"The main requirement for success is that Kiniksa Pharmaceuticals International converts its early ARCALYST traction and data- and technology-driven commercial model into sustained uptake across a much larger share of eligible recurrent pericarditis prescribers and patients."

Q3 results show real progress toward that hurdle. ARCALYST revenue reached US$286m, prescribers increased to about 5,450, and penetration in the 14,000 multiple recurrence pool moved to 23%. Collaboration profit grew faster than sales, which supports the claim that AI and DTC spend are translating into both volume and earnings efficiency.

One Narrative disagrees with today's price. → See where this Narrative says Kiniksa Pharmaceuticals International should trade.

Kiniksa bears focus on ARCALYST concentration cracks

Bears argue Kiniksa Pharmaceuticals International is one soft quarter away from exposing over reliance on a single therapy. The key concern reads:

"Although Kiniksa Pharmaceuticals International is seeing broader use of IL‑1 inhibition in recurrent pericarditis, reliance on continued expansion into the roughly 79% of multiple‑recurrence patients who are not yet on ARCALYST creates significant downside risk if prescriber additions or earlier‑line adoption stall, which would weigh on revenue growth and limit operating leverage."

Q3 does not show that stall. Prescribers reached about 5,450 and multiple recurrence penetration moved to 23%. The real miss is diversification. KPL‑387 only has pivotal data guided for H2 2027 and KPL‑1161 remains pre first in human, so ARCALYST concentration risk is unchanged.

Hunt Quiet Disconnects In Plain Sight

Kiniksa Pharmaceuticals International shows how quickly sentiment can change when an earnings story gains clarity. The real opportunity is spotting stocks that could be undervalued before the market closes those gaps.

• Company 1 - 23% below our estimate - uses surgical robotics and higher acuity procedures to strengthen hospital ties and broaden orthopaedic procedure coverage.
• Company 2 - 31% below our estimate - sells GPU hardware and integrated AI software stacks that hyperscale data centres depend on for intensive workloads.
• Company 3 - 27% below our estimate - supplies grid diagnostics and testing systems utilities use as they modernize networks for heavier electrification and complex defense demands.

Three companies from the same screener. Open the full list of 29 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com